Immuneering Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $249.7M
- Price
- $3.86
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.78%
- Volume
- 747.7K
About
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Quick stats
Shares outstanding64.7M
Computed float56.0M
Float / shares86.5%
Cash runway (months)26.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001790340
Websitehttps://immuneering.com
AI Summary
AI-generated1/22
minorbullishclinical trial
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Immuneering will present a poster at the 41st Annual SITC meeting (November 4-8, 2026, Phoenix) showing that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant preclinical tumor models.
The findings provide mechanistic support for a planned Phase 2 study of atebimetinib combined with PD-1 blockade in lung cancer patients.
Atebimetinib is Immuneering's lead oral, once-daily MEK inhibitor; the company is also running the pivotal MAPKeeper 301 trial in first-line pancreatic cancer.